Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Core Insights - Bolt Biotherapeutics, Inc. reported a quarterly loss of $3.72 per share, which was better than the Zacks Consensus Estimate of a loss of $5.07, marking an earnings surprise of +26.63% [1] - The company generated revenues of $2.17 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 294.36% and showing an increase from $1.14 million in the same quarter last year [2] - The stock has underperformed, losing approximately 55.1% since the beginning of the year, while the S&P 500 has gained 16.4% [3] Financial Performance - Over the last four quarters, Bolt Biotherapeutics has surpassed consensus EPS estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$4.85 on revenues of $0.5 million, and for the current fiscal year, it is -$20.72 on revenues of $4.07 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Bolt Biotherapeutics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]